Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events

PURPOSE: To assess safety and effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in IBD patients ≥ 60 years. METHODS: Ninety IBD patients ≥ 60 years at initiation of anti-TNF therapy, 145 IBD patients ≥ 60 years without anti-TNF therapy and 257 IBD patients < 60 years at initiation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Asscher, Vera E. R., van der Vliet, Quirine, van der Aalst, Karen, van der Aalst, Anniek, Brand, Eelco C., van der Meulen-de Jong, Andrea E., Oldenburg, Bas, Pierik, Marieke J., van Tuyl, Bas, Mahmmod, Nofel, Maljaars, P. W. Jeroen, Fidder, Herma H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648742/
https://www.ncbi.nlm.nih.gov/pubmed/32860081
http://dx.doi.org/10.1007/s00384-020-03716-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648742/
https://www.ncbi.nlm.nih.gov/pubmed/32860081
http://dx.doi.org/10.1007/s00384-020-03716-6

Ejemplares similares